Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healthlead PCL has the GF Score of 76, which implies that the company
is
Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Healthlead PCL
is
Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Healthlead PCL (BKK:HL) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Healthlead PCL GF Score Related Terms
Healthlead PCL GF Score Competitor Comparison
For the Pharmaceutical Retailers subindustry, Healthlead PCL's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healthlead PCL GF Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Healthlead PCL's GF Score distribution charts can be found below:
* The bar in red indicates where Healthlead PCL's GF Score falls into.
Healthlead PCL (BKK:HL) has a GF Score of 76 as of Jul. 19, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Healthlead PCL and its competitors. This is 245% above median its historical median of 22.00. Over the past decade, Healthlead PCL's GF Score has ranged from 14.00 to 85.00.
Is Healthlead PCL's GF Score too high?
Healthlead PCL's current GF Score of 76 is 245% above median its 10-year median of 22.00. Over the past 10 years, this metric has ranged from a low of 14.00 to a high of 85.00. Overall, Healthlead PCL has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthlead PCL's GF Score compare to competitors?
Healthlead PCL's GF Score of 76 can be compared against companies in the Healthcare Providers & Services industry. Historically, Healthlead PCL's own GF Score has ranged from 14.00 to 85.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Healthcare Providers & Services company?
A good GF Score depends on the Healthcare Providers & Services industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Healthlead PCL and its competitors. Healthlead PCL's current GF Score is 76, which is 245% above median its own 10-year median of 22.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthlead PCL stock overvalued right now?
Based on GuruFocus' analysis, Healthlead PCL (BKK:HL) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿10.89, compared to a current price of ฿5.80 — trading 46.7% below its estimated fair value. The current GF Score is 76, which is 245% above median its 10-year median of 22.00. Healthlead PCL's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Healthlead PCL (BKK:HL), the current GF Score is 76 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healthlead PCL (BKK:HL) Overvalued in 2026?
Based on GuruFocus' analysis, Healthlead PCL stock appears to be undervalued.
The current stock price of ฿5.80 is trading 46.7% below its estimated GF Value™ of ฿10.89.
GuruFocus considers Healthlead PCL to be Significantly Undervalued.
Key valuation signals for BKK:HL:
GF Score: 76 (245% above median its 10-year median of 22.00)
GF Value™: ฿10.89 vs. price of ฿5.80 (46.7% below fair value)
No single metric tells the full story. See the BKK:HL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healthlead PCL is a holding company. Along with its subsidiaries, it operates a pharmacy business under iCare, Pharmax, vitaminclub, and Super Drug brands, distributing medicines, medical supplies, cosmeceuticals, dietary supplements, medical devices, and other healthcare products. Additionally, it is involved in co-inventing and co-developing healthcare products in collaboration with external research teams and contract manufacturers, producing and distributing its own branded products. Geographically, the group operates only in Thailand.
76GF Score
Get the complete analysis for BKK:HL
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:HL has been successfully added to your 
